This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Parkinson’s disease basic panel [8 genes]
The term Parkinsonism refers to a group of neurological syndromes characterized by bradykinesia, muscle stiffness, resting tremor, and postural instability. Parkinson’s disease is the most common form of parkinsonism and the second most frequent neurodegenerative disease after Alzheimer’s disease. It is clinically characterized by these four cardinal motor symptoms, as well as by a good response to treatment with levodopa. Its prevalence is estimated to be between 1%-2% of the population at age 65 and about 4% at age 85. Approximately 15% of cases are familial, although some studies suggest that up to 60% of sporadic cases could be explained by genetic risk factors (Hamza et al., 2010). It is currently considered a multifactorial disease, with numerous environmental and genetic factors involved.
The most commonly involved monogenic determinants have been selected for a basic panel for this disease, including SNCA, LRRK2, and VPS35 (with autosomal dominant transmission and generally late onset), and PRKN (PARK2), PINK1, PARK7 (DJ1), and VPS13C (with autosomal recessive transmission and an earlier onset). This panel also includes the GBA gene, which is associated with a greater risk of developing the disease.
For the study of early-onset parkinsonism, usually appearing during adolescence (<20 years), we have developed a specific panel with the most common causative genes.
Other types of atypical parkinsonism and Parkinson-plus disorders (such as progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, or Lewy body dementia) are covered by the comprehensive panel.
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Parkinson's disease basic panel
Turnaround time (TAT): 6 weeks
Ref. S-202008632
- GBA
- LRRK2
- PARK7
- PINK1
- PRKN
- SNCA
- VPS13C
- VPS35
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.
- Hamza TH, Payami H. The heritability of risk and age at onset of Parkinson’s disease after accounting for known genetic risk factors. J Hum Genet. 2010 Apr;55(4):241-3.